Medipixel
Founded 2017 Β· 38 employees on LinkedIn Β· 6 known investors
Medipixel develops AI-based clinical solutions in the medical technology field, working with hospitals and healthcare partners. The company combines medical technology with clinical expertise to support diagnosis and treatment.
Also known as Medipixel, Inc. Β· λ©λν½μ
Investors Β· 6
Company profile
researched Aug 2026Medipixel, Inc. is a Seoul-based medical technology company that develops AI-based software as a medical device (SaMD) for image analysis in interventional procedures. Its principal offering is an AI-powered coronary analysis platform that spans the workflow from coronary angiography image acquisition through automated vessel segmentation and quantitative lesion analysis (MPXA) to AI-based fractional flow reserve (FFR) functional assessment (MPFFR). The company states that its Medipixel X-ray Angiography product holds Korean Ministry of Food and Drug Safety (MFDS) certification and U.S. FDA clearance, and that its angiography-derived physiology product holds MFDS certification and has been designated as a new health technology with deferred assessment.
Beyond coronary work, Medipixel offers MPNeuro, a cerebrovascular digital twin SaMD with MFDS certification that uses an AI engine to build and analyze three-dimensional cerebrovascular geometry, allowing clinicians to adjust regions of interest and viewing planes during diagnosis. Its product line also includes MPXA CoreLab (released 2025, a research-only, non-medical-device tool for retrospective cardiovascular quantitative analysis with frame recommendation, vessel segmentation and lesion analysis), MPXA Hub, MPXA Report and MPIV.
Earlier company descriptions characterize Medipixel as a MedTech startup formed by specialists in computer vision, deep learning and reinforcement learning, conducting research and product development on lung cancer diagnosis and coronary intervention robots with Korean healthcare institutions including Seoul Asan Medical Center. That description lists three solutions for interventional physicians: an AI-based diagnosis solution that detects lesions during angiography and segments the vessel within about one second; a guide-and-planning solution that visualizes obscured coronary segments to assist guidewire manipulation, particularly in chronic total occlusion (CTO) cases and with reduced reliance on contrast agents; and an automated navigation engine that navigates coronary arteries and issues real-time commands to a robotic unit to deliver devices such as guidewires.
Founding story
Medipixel was founded in 2017 by Andy Song, who holds a bachelor's degree from Korea University and a master's degree in computer science from Carnegie Mellon University. Before founding the company he worked at LG Electronics and Tongyang Systems, then spent years as an engineer at AhnLab from 2001 building enterprise e-mail gateway and application firewall products; in 2006 he was selected to lead AhnLab's first in-house venture team, which was spun off in 2010 as Noritown Studio, where he served as CEO for about three and a half years. He founded Medipixel to help clinicians diagnose and treat cardiovascular disease more quickly and accurately.
Business model
Medipixel develops and commercializes regulated software medical devices and research software sold to hospitals and interventional cardiology and neurointervention practices, supported by a demo-request sales motion on its website and a partner network.
Traction
The company reports clinical evidence for its AI analysis, including an F1 score of 0.91 for vessel segmentation and lesion detection, FFR functional assessment accuracy of 0.949 by AUC, and automated analysis completed in under 10 seconds to support intra-procedural decisions. It cites cumulative investment, patents and partner counts on its overview page, and its products carry MFDS and FDA certifications.
Latest developments
MPXA CoreLab, a research-use retrospective cardiovascular quantitative analysis solution using reinforced AI training, was released in 2025. Executive updates recorded for the company include a VP listing in February 2025 and a CFO listing in May 2024.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Medipixel positions itself as a specialist in AI analysis for cardiovascular interventional procedures, with regulatory clearances in Korea and the United States and clinical validation studies cited for its analysis accuracy.
Medipixel emphasizes real-time analysis integrated into the catheterization lab workflow, combining image-based vessel and lesion quantification with AI-derived functional (FFR) assessment, and extending the approach to cerebrovascular digital twin modeling and robotic guidewire navigation.
Technology
The platform applies artificial intelligence to X-ray coronary angiography for automated vessel segmentation and quantitative lesion analysis, and to angiography-derived physiology for functional ischemia assessment. The company also applies computer vision, deep learning and reinforcement learning to 3D cerebrovascular reconstruction and to automated navigation engines that issue real-time control commands to interventional robotic units. Published open-source work includes reinforcement learning algorithm implementations and object detection tutorials.
Go-to-market
Direct engagement through website demo requests and contact forms, a named partner program, and collaboration with Korean healthcare institutions and clinicians; the business group is led by a VP of Sales and Marketing with prior roles at Johnson & Johnson, Janssen and Boston Scientific.
Interventional cardiologists and neurointerventional clinicians in catheterization labs, hospitals such as Seoul Asan Medical Center, and core-lab researchers performing retrospective cardiovascular image analysis.
Geography
Headquartered in Seoul, South Korea, with U.S. FDA certification cited for its X-ray angiography product and stated ambitions for use in global medical settings.
History
The company has focused on cardiovascular interventional procedures since 2017. In November 2018 it won the championship of the Johnson & Johnson QuickFire Challenge. Seed investment was reported in Korean startup media. Danny Jeong joined as CTO and Haegeun Song as CMO in 2023, and MPXA CoreLab was released in 2025.
Risks & controversies
MPXA CoreLab is explicitly stated not to be a medical device and is limited to research use; the company's other products depend on regulatory certifications from the Korean MFDS and the U.S. FDA.
Compiled by commissioned research from 6 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 8
launches, deals, and filingsResearch-use solution providing retrospective cardiovascular quantitative analysis with frame recommendation, vessel segmentation and lesion analysis; stated not to be a medical device.
The company states its X-ray angiography product is certified by Korea's Ministry of Food and Drug Safety and by the U.S. FDA.
Jeong joined Medipixel in 2023 as CTO and Head of R&D, previously Head of R&D center at AhnLab and CTO at Kai-i Company.
A cardiologist with a medical Ph.D. from Ulsan University and prior professorship in cardiology at Chung-Ang University, Song joined as CMO in 2023.
Korean outlet Platum reported that medical AI startup Medipixel raised seed investment.
Medipixel won the championship in the QuickFire Challenge hosted by Johnson & Johnson.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 6
primary sources listed
- Medipixelmedipixel.io Β· web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medipixel do?
- Korean medical AI company building software that analyzes coronary angiography images and assesses vessel function during interventions.
- Who are Medipixel's investors?
- Medipixel's investors include Ascendo Ventures, Company K Partners, Mirae Asset Venture Investment, Premier Partners, AI Angel Club, Ascendo Ventures.